Telemonitoring of Treatment Effects in Connective Tissue Disease-associated Interstitial Lung Disease (TEL-CTD-ILD)

  • STATUS
    Recruiting
  • End date
    Apr 25, 2022
  • participants needed
    60
  • sponsor
    Medical Universtity of Lodz
Updated on 25 January 2021
remission
immunosuppressant
immunosuppressive
dyspnea
pulmonary disease
oximetry
immunosuppressants
lung disease
spirometry
rheumatism
interstitial lung disease

Summary

  1. Impact of telemonitoring on quality of life (QoL) of patients with CTD-ILD
  2. Evaluation of health status of patients with connective tissue disease-associated interstitial lung disease (CTD-ILD) using telemonitoring and standard care.
  3. Assessment of treatment response patterns (full remission, partial remission, progression, no response) and evaluation of clinical prognostic factors (risk factors for poor response in patients with CTD-ILD.
  4. Evaluation of cost-effectiveness of telemonitoring solutions in patients with CTD-ILD.
  5. Evaluation of telemedicine as a tool for assessing the safety of therapy

Description

Interstitial lung disease (ILD) is one of the most serious pulmonary complications related to connective tissue diseases (CTDs), resulting in substantial morbidity and mortality. Interstitial lung disease is a common manifestation of different connective tissue diseases, such as scleroderma, rheumatoid arthritis (RA), Sjgren's syndrome, systemic lupus, dermatomyositis and others. Radiological and histopathological patterns are most often nonspecific interstitial pneumonia (NSIP), organizing pneumonia (OP), usual interstitial pneumonia (UIP) and lymphocytic interstitial pneumonia (LIP).

Current standard of care in progressive CTD associated ILD is low to medium dose of corticosteroids, frequently combined with immunosuppressive medication, depending on disease severity and local standards. However, based on clinical and radiological features, it is difficult to predict what will be the response to the treatment. Effectiveness of the treatment is assessed by functional tests and chest high resolution computed tomography (HRCT), performed usually after 3 months of therapy.

Project objective is to assess the possible benefits of using telemonitoring of functional and vital signs, symptoms and quality of life of patients with CTD-ILD in response to treatment.

In the trial patients diagnosed with CTD-ILD will be randomized to intervention group (telemonitoring) and the control group (traditional assessment). Patients from the study after initial training will perform daily spirometry (FVC), transdermal pulse oximetry, pulse and blood pressure measurements, activity measurement (accelerometry), and assessment of severity of cough and dyspnea. The additional questionnaires will also be used to assess the tolerability of treatment, quality of life and the occurrence of side effects. Telemonitoring will start 10 to 14 days before the start of treatment and will be carried out for 3 months of therapy. All patients (study and control group) will receive treatment in accordance with current treatment standards. During the 3-month observation period, visits to the center will take place at monthly intervals. In the case of treatment intolerance or deterioration of monitored parameters, patients will be evaluated at additional time points. All patients after the end of the 3-month follow-up will remain under the care of the Pulmonology Clinic and will be examined during regular visits every 3 months until the end of the 12-month follow-up period.

Details
Condition Pulmonary Disease, CONNECTIVE TISSUE DISEASE, Pulmonary Fibrosis, Interstitial lung disease, Dermatomyositis (Connective Tissue Disease), Connective Tissue Diseases, Lung Disease, Connective Tissue Disease-associated Interstitial Lung Disease, Connective Tissue Disease-associated Interstitial Lung Disease, connective tissue disorder, interstitial lung diseases, Connective Tissue Disease-associated Interstitial Lung Disease
Treatment telemonitoring
Clinical Study IdentifierNCT04428957
SponsorMedical Universtity of Lodz
Last Modified on25 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Newly diagnosed interstitial lung disease with a small component of fibrous changes
Indications for systemic glucocorticoid therapy +/- immunosuppressant
years and older
Informed consent to participate in the study
Effective contraception
Result of the Mini Mental test ensuring the possibility of efficient operation of monitoring devices
Completed training in the operation of telemedicine equipment

Exclusion Criteria

Evidence of irreversible interstitial fibrotic changes in lung HRCT
Pattern of definite or probable usual interstitial pneumonia (UIP) in the HRCT examination
Contraindications to glucocorticoid and immunosuppressive therapy (azathioprine or mycophenolate mofetil or cyclophosphamide or cyclosporine)
Pregnancy and breast-feeding
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note